U.S. Other Utilities Stock News

NasdaqGS:KMB
NasdaqGS:KMBHousehold Products

Is Kimberly-Clark (KMB) Undervalued After Its Earnings Beat And Reaffirmed Outlook

Kimberly-Clark (KMB) is back in focus after first quarter 2026 results topped analyst expectations, with organic sales growth, margin progress and reaffirmed guidance, even as management works through a distribution center fire and rising input costs. See our latest analysis for Kimberly-Clark. Even with the recent earnings beat and reaffirmed outlook, Kimberly-Clark's share price has been under pressure, with a year to date share price return of 3.68% decline and a 1 year total shareholder...
NYSE:ASH
NYSE:ASHChemicals

Does Ashland's (ASH) Trimmed Sales Outlook and Buybacks Recast Its Margin-Resilience Story?

In the past week, Ashland Inc. reported second-quarter fiscal 2026 results showing sales of US$482 million and net income of US$16 million, alongside updated full-year 2026 sales guidance to a range of US$1,835 million to US$1,870 million. The company also confirmed it has now completed its June 28, 2023 share repurchase program, having bought back 5,826,514 shares for US$480.07 million, reshaping its capital allocation profile as it contends with softer demand and operational headwinds. Now...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics (GPCR) Is Down 7.2% After Strong Phase 2 Oral GLP‑1 Obesity Data – Has The Bull Case Changed?

Structure Therapeutics previously reported encouraging Phase 2 ACCESS II trial results for its oral GLP-1 receptor agonist aleniglipron, showing up to 16.3% weight reduction in adults with obesity and outlining plans to meet the FDA in Q2 2026 ahead of Phase 3 trials in the second half of 2026. The data position aleniglipron as one of the most effective oral GLP-1 candidates so far, highlighting a potentially meaningful differentiation versus other pill-based obesity treatments. Next, we...
NasdaqGM:SHLS
NasdaqGM:SHLSElectrical

How Shoals’ Governance Rifts on Executive Pay and Board Equity Could Shape Shoals Technologies (SHLS)

Shoals Technologies Group recently held its 2026 Annual Meeting, re-electing five directors, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as auditor, while directors received new restricted stock unit grants with varying vesting and deferral schedules. The mixed shareholder support for executive compensation, alongside rising director equity stakes and Vanguard’s more than 5% ownership, highlights growing investor focus on governance and alignment of...
NYSE:DD
NYSE:DDChemicals

Is It Too Late To Consider DuPont De Nemours (DD) After Its 68% One-Year Rally?

Wondering whether DuPont de Nemours is still priced attractively after its recent run, or if the easy value has already been taken off the table. The stock last closed at US$46.24, with returns of 13.1% year to date and 67.8% over the past year, following a more muted 1.7% return over 30 days and a 0.2% slip over the last week. Recent news coverage has focused on DuPont de Nemours as a major name in the US materials space, with investors paying close attention to how the company positions...
NYSE:NEU
NYSE:NEUChemicals

Softer Q1 Results and Cash Returns Could Be A Game Changer For NewMarket (NEU)

NewMarket Corporation recently reported first-quarter 2026 results showing sales of US$669.72 million and net income of US$118.07 million, both lower than a year earlier, and its board declared a US$3.00 per-share dividend payable on July 1, 2026 to shareholders of record on June 15, 2026. Alongside these results, NewMarket completed a share repurchase of 337,201 shares for US$197.36 million, reducing its share count while continuing to return cash through dividends. We’ll now examine how...
NYSE:NSP
NYSE:NSPProfessional Services

Assessing Insperity (NSP) Valuation After A Steep One Year Shareholder Return Decline

Insperity stock performance snapshot Insperity (NSP) has drawn attention after a series of weak returns, including a 20% one day decline and a 54% total return decline over the past year, prompting closer scrutiny from investors. See our latest analysis for Insperity. The 1 day share price return of 19.79% and 7 day share price return of 12.94% add to a 90 day share price return of 33.88%. The 1 year total shareholder return of 54.47% underlines how recent weakness builds on a longer slide in...
NasdaqGS:NVDA
NasdaqGS:NVDASemiconductor

Is It Time To Reassess Nvidia (NVDA) After Its Recent Share Price Swings?

If you are wondering whether NVIDIA's current share price reflects its true worth, you are not alone. Many investors are asking the same question right now. The stock last closed at US$198.45, with a 4.7% decline over 7 days, an 11.9% gain over 30 days, a 5.1% gain year to date, a 73.4% gain over 1 year and a very large return over 3 and 5 years. Recent headlines continue to highlight NVIDIA's central role in areas such as AI infrastructure, graphics processing and data center hardware,...
NYSE:AAMI
NYSE:AAMICapital Markets

Is It Too Late To Consider Acadian Asset Management (AAMI) After Its 1-Year Surge?

If you are wondering whether Acadian Asset Management is still attractively priced after a strong run, the starting point is understanding what the current market price is implying about the business. The stock closed at US$65.49, with recent returns of 18.5% over 30 days, 38.2% year to date, and 135.9% over 1 year, although the last 7 days showed a 3.4% decline. Recent coverage has focused on Acadian Asset Management's share price performance and how investors are reacting to changing...